High-dose rifampicin — Competitive Intelligence Brief

High-dose rifampicin (High-dose rifampicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin antibiotic. Area: Infectious Disease.

phase 3 Rifamycin antibiotic Bacterial RNA polymerase Infectious Disease Small molecule

Target snapshot

High-dose rifampicin (High-dose rifampicin) — Seoul National University Hospital. High-dose rifampicin inhibits bacterial RNA polymerase to suppress mycobacterial growth and modulate immune responses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
High-dose rifampicin TARGET	High-dose rifampicin	Seoul National University Hospital	phase 3	Rifamycin antibiotic	Bacterial RNA polymerase
Rifaximin oral tablet	Rifaximin oral tablet	Yokohama City University	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifaximin (drug)	Rifaximin (drug)	Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
amoxicillin rifabutin	amoxicillin rifabutin	Shanghai Jiao Tong University School of Medicine	marketed	Combination antibiotic (beta-lactam + rifamycin)	Penicillin-binding proteins (amoxicillin); bacterial RNA polymerase (rifabutin)
Rifampin/isoniazid/pyrazinamide/ethambutol FDC	Rifampin/isoniazid/pyrazinamide/ethambutol FDC	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Anti-tuberculosis agent (fixed-dose combination)	Bacterial RNA polymerase (rifampin), mycolic acid synthesis (isoniazid), membrane potential/energy metabolism (pyrazinamide), arabinosyl transferase (ethambutol)
Rifabutin/rifampin	Rifabutin/rifampin	The University of Texas Health Science Center at Tyler	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifampicin (RIF)	Rifampicin (RIF)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Rifamycin antibiotic	Bacterial RNA polymerase (RNAP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rifamycin antibiotic class)

1. Institute of Tropical Medicine, Belgium · 2 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Bausch Health Americas, Inc. · 2 drugs in this class
5. South China Children's Leukemia Group · 1 drug in this class
6. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 drug in this class
7. TenNor Therapeutics (Suzhou) Limited · 1 drug in this class
8. The University of Texas Health Science Center at Tyler · 1 drug in this class
9. University College, London · 1 drug in this class
10. University of California, San Francisco · 1 drug in this class